INTRODUCTION {#sec1}
============

In 2018, there were an estimated 18.1 million new cancer cases and 9.6 million cancer deaths, worldwide. Lung cancer is the most commonly diagnosed cancer worldwide, constituting 11.6% of total cancer cases, and is the leading cause of cancer death (18.4% of total cancer deaths)^[@cit0001]^.

Smoking is a major contributor to the pathogenesis of lung cancer^[@cit0002]^. Even exposure to secondhand tobacco smoke increases the risk of developing lung cancer among non-smokers^[@cit0003],[@cit0004]^. The pro-carcinogens specific to tobacco are clearly implicated in the progression of lung malignancies^[@cit0005],[@cit0006]^. However, not all smokers will eventually develop lung cancer in their lifetime. These individual differences in lung cancer morbidity could be due to other determinants such as genetic susceptibility^[@cit0007],[@cit0008]^ and environmental factors^[@cit0009]-[@cit0011]^. Thus, it is important to identify the genetic variants that influence the risk of lung cancer initiation^[@cit0012],[@cit0013]^.

Most tobacco carcinogens require metabolic activation, which is mainly executed by the cytochrome P450 (CYP) enzymes^[@cit0014]^. Electrophile agents with short lifespans (which are produced in metabolic activation) cross-react with DNA, causing DNA damage and initiating tumours^[@cit0015],[@cit0016]^. Among the CYP isozymes, CYP family 2 subfamily A member 6 (*CYP2A6*) is responsible for nicotine metabolism and for the metabolic activation of the tobacco-specific pro-carcinogens *N*-nitrosamine *N*-nitrosonornicotine (NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), which can eventually contribute to the progression of lung cancer^[@cit0005]^.

Genetic polymorphism is defined as the inheritance of a trait controlled by a single genetic locus with two alleles in which the least common allele has a frequency of approximately ≥1% that can cause variation in the DNA sequence in individuals, groups, or populations^[@cit0017]^. The difference in DNA sequence may not alter the overall product sufficiently enough to produce a different protein but may affect the specific activity of the enzyme, and binding efficiencies such as those for transcription factors or membrane proteins, or other features and function^[@cit0018]^. Thus, Cytochrome P450 2A6 (*CYP2A6*) polymorphism can influence how humans metabolize xenobiotics.

Over the past two decades, several studies have assessed the association between *CYP2A6* polymorphism, including whole-gene deletion of *CYP2A6* on allele 4 (*CYP2A6\*4*), and the risk of lung cancer among different ethnic populations, but the results have been inconsistent^[@cit0012],[@cit0019],[@cit0020]^. Therefore, the present meta-analysis was performed to determine the association between *CYP2A6* whole-gene deletion (*CYP2A6\*4*) polymorphism and lung cancer risk.

METHODS {#sec2}
=======

Literature search {#sec2.1}
-----------------

This meta-analysis was performed based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement^[@cit0021]^. A literature search was performed on five databases, namely PubMed, SAGE, ScienceDirect, the Cochrane Library, and Ovid. The search strategy utilized the PICO (Population, Intervention, Comparison, Outcome) framework to improve searching for clinical questions^[@cit0022]^. The search terms used were: \['cytochrome P450 2A6' OR '*CYP2A6*'\] AND \['lung cancer' OR 'pulmonary cancer' OR 'respiratory cancer'\]. The search was not restricted to any duration or timeline.

Study selection {#sec2.2}
---------------

Two pairs of reviewers conducted the study selection in two phases after duplicate studies had been excluded. In the first phase, two reviewers (MSAM and MHA) independently screened the titles and abstracts of potential articles to be included in the study. During this phase, irrelevant studies were excluded, and a third reviewer (FHJ) resolved any disagreements. In the second phase, full-text articles were retrieved for detailed evaluation. Studies were included if they were published prior to October 2018 and met the following criteria: 1) observational study design, 2) presence of *CYP2A6* whole-gene deletion (*CYP2A6\*4*) polymorphism, and 3) presence of lung cancer. We excluded studies that were not published in English, reviews, case reports or animal studies, or if the full text was not available.

Data extraction {#sec2.3}
---------------

Articles that met the inclusion and exclusion criteria were retained for a full review. The characteristics of each study were examined and included study design, study location, type of population, sample size, sex, smoking status, matching criteria, genotyping method and genotype, and risk estimate value.

Assessment of methodological quality {#sec2.4}
------------------------------------

Two authors assessed the quality of the selected articles independently, using the Newcastle-Ottawa Quality Assessment Scale (NOS)^[@cit0023]^ to examine for the concordance and average NOS score for each study. The NOS is widely used for quality assessment of observational studies^[@cit0024],[@cit0025]^. It evaluates three components to quantify study quality, i.e. selection of study subjects, comparability of study groups and exposure or outcome ascertainment, which consists of eight items with a maximum score of 9 for each study. The scores of each item indicate the methodological quality of the study. A study is categorized as being of high, moderate or low quality, based on a total score of 7--9, 4--6 and 0--3, respectively^[@cit0026]^.

Meta-analysis {#sec2.5}
-------------

The random-effects model^[@cit0027]^ was used to estimate the pooled effect size from the included studies. Odds ratio (OR) with 95% confidence interval (CI) and a statistical measure of heterogeneity (χ^[@cit0002]^ and I^[@cit0002]^) were calculated using Review Manager 5.3^[@cit0028]^. All selected studies were included in the meta-analysis. Subgroup and sensitivity analyses were performed if p\<0.10 and I^[@cit0002]^ ≥50%.

RESULTS {#sec3}
=======

The search strategy returned a total of 172 articles. Initial screening excluded 35 articles due to duplication. Further screening of titles and abstracts excluded 41 irrelevant studies and nine review articles. The eligibility of the remaining 87 articles was assessed: 40 were excluded for studying different outcomes such as smoking behaviour, 28 were excluded for studying different exposures such as other CYP450 genotypes, eight were excluded as we were unable to extract raw data related to the whole deletion of allele \*4/\*4, while two articles were excluded because we did not find data related to the whole deletion of allele \*4/\*4 in the studies. The remaining nine articles^[@cit0012],[@cit0020],[@cit0029]-[@cit0035]^ were included in the meta-analysis. [Figure 1](#f0001){ref-type="fig"} depicts the flow diagram describing article retrieval based on the PRISMA flow diagram^[@cit0021]^. The studies were carried out in Japan, China, Bangladesh, and Italy. Eight studies used Asian samples and only one study^[@cit0034]^ used Caucasian samples. [Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"} present the characteristics of the included studies.

###### 

Characteristics of studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Study*                       *Year Country & Population*   *Study design (cases/controls)*   *Gender, Smoking status*   *Matching criteria*           *Genotyping methods*    *Histological type (%)*   *CYP2A6 genotype*         *Crude OR (95% CI)*
  ----------------------------- ----------------------------- --------------------------------- -------------------------- ----------------------------- ----------------------- ------------------------- ------------------------- ---------------------------------------------------------------
  Hosono et al.^[@cit0012]^     2015 Japan\                   Case-control\                     Both\                      Age, sex                      PCR-Goodz and Tyndale   SQCC (100)                Group 1: 1/1\             Group 1: 1 (Ref.)\
                                Asian                         110/132                           All smoker                                                                                                 Group 2: 1/7, 1/9,\       Group 2: 1.00 (0.49--2.07)\
                                                                                                                                                                                                           1/10, 1/13, 1/15, 8/9\    Group 3: 0.71 (0.35--1.45)\
                                                                                                                                                                                                           Group 3: 1/4, 1/41,\      Group 4: 0.13 (0.04--0.45)\
                                                                                                                                                                                                           1/567C\>T, 7/9, 7/11,\    Group 5: 0.15 (0.03--0.82)
                                                                                                                                                                                                           7/13, 9/9, 9/11\          
                                                                                                                                                                                                           Group 4: 4/7, 4/9,\       
                                                                                                                                                                                                           4/13, 4/18, 7/567C\>T\    
                                                                                                                                                                                                           Group 5: 4/4, 4/5         

  Islam et al.^[@cit0029]^      2013\                         Case-control\                     Both\                      Age, sex, smoking status      PCR-RFLP                SQCC (43.39)\             Group 1: 1A/1A,\          Group 1: 1 (Ref.)\
                                Bangladesh\                   106/116                           Mixed                                                                            AC (34.91\                1A/1B1, 1B1/1B1.\         Group 2: 0.40 (0.17--0.91)
                                Asian                                                                                                                                            SCC (18.87)\              Group 2: 1A/4,\           
                                                                                                                                                                                 ASQC (0.94)               1B1/4. 4/4                

  Tamaki et al.^[@cit0030]^     2011 Japan\                   Case-control\                     Both\                      Age, sex                      PCR- Oscarson           AC (41.7)\                Group 1: non-4/\          Group 1: 1 (Ref.)\
                                Asian                         192/203                           Mixed                                                                            SQCC (24.5)\              non-4\                    Group 2: 0.92 (0.60--1.42)\
                                                                                                                                                                                 SCC (21.4)\               Group 2: non-4/4\         Group 3: 0.36 (0.14--0.88)
                                                                                                                                                                                 ASQC (2.1)\               Group 3: 4/4              
                                                                                                                                                                                 LCC (0.5)\                                          
                                                                                                                                                                                 Unknown (3.6)                                       

  Rotunno et al.^[@cit0034]^    2009 Italy\                   Case-control\                     Both\                      Age, sex, area of residence   SNP Assays              AC (41)\                  Group 1: T/T\             Group 1: 1 (Ref.)\
                                Caucasian                     1859/2019                         Mixed                                                                            SQCC (25.6)\              Group 2: T/A\             Group 2: 0.74 (0.55--1.00)\
                                                                                                                                                                                 SCC (10.2)\               Group 3: A/A              Group 3: 0.26 (0.04--1.94)
                                                                                                                                                                                 Other (21.5)\                                       
                                                                                                                                                                                 Unknown (1.8)                                       

  Fujieda et al.^[@cit0031]^    2004 Japan\                   Case-control\                     Both\                      No matching                   PCR-RFLP                SQCC (26.9)\              Group 1: 1/1\             Group 1: 1 (Ref.)\
                                Asian                         1094/611                          All smokers                                                                      SCC (12.2)\               Group 2: 1/4, 1/7,\       Group 2: 0.59 (0.44--0.79)[^a^](#tf1-1){ref-type="table-fn"}\
                                                                                                                                                                                 AC (50.9)\                1/9, 1/10, 1/11\          Group 3: 0.52 (0.37--0.72)^a^\
                                                                                                                                                                                 Unknown\                  Group 3: 4/7, 4/9,\       Group 4: 0.30 (0.16--0.57)[^a^](#tf1-1){ref-type="table-fn"}
                                                                                                                                                                                 (10.0)                    4/10, 4/11, 7/7, 7/9,\    
                                                                                                                                                                                                           7/10, 9/9, 9/10, 9/11,\   
                                                                                                                                                                                                           10/10\                    
                                                                                                                                                                                                           Group 4: 4/4              

  Ariyoshi et al.^[@cit0032]^   2002 Japan\                   Case-control\                     Both\                      No matching                   PCR-Bell                SCC (11.9)\               Group 1: 1A/1A\           Group 1: 1 (Ref.)\
                                Asian                         370/380                           All smokers                                                                      SQCC (28.4)\              Group 2: 1A/1B\           Group 2: 0.70 (0.46--1.07)\
                                                                                                                                                                                 AC (52.1)\                Group 3: 1B/1B\           Group 3: 0.60 (0.37--0.99)\
                                                                                                                                                                                 Others (7.6)              Group 4: 1A/4\            Group 4: 0.57 (0.33--0.97)\
                                                                                                                                                                                                           Group 5: 1B/4\            Group 5: 0.56 (0.34--0.92)\
                                                                                                                                                                                                           Group 6: 4/4              Group 6: 0.18 (0.06--0.50)

  Tan et al.^[@cit0020]^        2001 China\                   Case-control\                     Both\                      Age, sex                      PCR-Oscarson            SCC (58.3)\               Group 1: 1/1\             Group 1: 1 (Ref.)\
                                Asian                         151/326                           Mixed                                                                            AC (31.1)\                Group 2: 1/4, 4/4         Group 2: 2.0 (1.2--3.2)
                                                                                                                                                                                 Other (10.6)                                        

  Miyamoto et al.^[@cit0033]^   1999 Japan\                   Case-control\                     Both\                      No matching                   NA                      NA                        Group 1: Wild/Wild\       Group 1: 1 (Ref.)\
                                Asian                         246/201                           NA                                                                                                         Group 2: Wild/Conv.\      Group 2: 0.59 (0.34--1.02)\
                                                                                                                                                                                                           Group 3: Conv./Conv.\     Group 3: 0.57 (0.30--1.08)\
                                                                                                                                                                                                           Group 4: Wild/Del.\       Group 4: 0.29 (0.14--0.59)\
                                                                                                                                                                                                           Group 5: Conv./Del.\      Group 5: 0.46 (0.23--0.92)\
                                                                                                                                                                                                           Group 6: Del./Del.        Group 6: 0.25 (0.08--0.83)

  Kamataki et al.^[@cit0035]^   1999 Japan\                   Case-control\                     Both\                      No matching                   PCR-RFLP                NA                        NA                        NA
                                Asian                         257/154                           NA                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for age and smoking habit.

PCR-RFLP: Polymerase Chain Reaction - Restriction Fragment Length Polymorphism. Del: Deletion-type, Conv: Conversion-type. SQCC: Squamous Cell Carcinoma. AC: Adenocarcinoma. SCC: Small Cell Carcinoma. ASQC: Adenosquamous Cell Carcinoma. LCC: Large Cell Carcinoma.

###### 

Genotype frequencies of CYP2A6\*4 in studies included in the meta-analysis

  *Author*                      *Year*   *Case Genotype*   *Control Genotype*                     
  ----------------------------- -------- ----------------- -------------------- ------ ---- ----- ------
  Hosono et al.^[@cit0012]^     2015     2                 32                   76     8    48    76
  Islam et al.^[@cit0029]^      2013     1                 8                    97     4    18    94
  Tamaki et al.^[@cit0030]^     2011     7                 63                   122    19   66    118
  Rotunno et al.^[@cit0034]^    2009     2                 101                  1756   4    160   1855
  Fujieda et al.^[@cit0031]^    2004     25                301                  768    28   186   397
  Ariyoshi et al.^[@cit0032]^   2002     5                 98                   267    19   117   244
  Tan et al.^[@cit0020]^        2001     1                 38                   112    5    46    275
  Miyamoto et al.^[@cit0033]^   1999     5                 48                   193    9    60    132
  Kamataki et al.^[@cit0035]^   1999     2                 \-                   255    6    \-    148

![Flow chart of studies selection](TID-18-50-g001){#f0001}

Two reviewers were independently assigned to score the NOS for each study individually. The correlation coefficient scores between the two authors were strong, with r = 0.91 ([Figure 2](#f0002){ref-type="fig"}). Overall, the studies had moderate methodological quality as scored on NOS (mean score: 6.0; range: 2.0--7.5). Four studies were of high quality (NOS score: 7.0-- 9.0)^[@cit0020],[@cit0029],[@cit0032],[@cit0034]^, four were of moderate quality (NOS score: 4.0--6.9)^[@cit0021],[@cit0031],[@cit0032],[@cit0034]^, and only one study was of low quality (NOS score: \<4.0)^[@cit0035]^. The shape and symmetry of the funnel plot of log OR from the nine studies indicated that there was no publication bias ([Figure 3](#f0003){ref-type="fig"}). All studies had a high precision value.

![The research quality assessment of each study was assessed using NOS with two independent reviewers.](TID-18-50-g002){#f0002}

![Funnel plot of the nine studies included in the meta-analysis](TID-18-50-g003){#f0003}

[Figure 4](#f0004){ref-type="fig"} shows the result of the meta-analysis using the random-effects model 28, which combined the nine studies to explore the association between the *CYP2A6\*4* polymorphism and the risk of lung cancer. The forest plot illustrates the spread of the studies' risk estimates and their CIs in relation to the pooled OR of meta-analysis. The pooled OR estimates showed that the *CYP2A6\*4* whole-gene deletion polymorphism significantly reduced the risk of lung cancer (pooled OR=0.39; 95% CI: 0.27--0.56). No heterogeneity was found across the studies (pheterogeneity = 0.96, I2=0%). Subgroup analysis according to smoking status ([Figure 5](#f0005){ref-type="fig"}) showed that the pooled OR estimate of the *CYP2A6\*4* whole-gene deletion polymorphism remained significantly protective against lung cancer among 'All Smoker Status' (pooled OR=0.41; 95% CI: 0.26--0.64), 'Mixed Smoking Status' (pooled OR=0.39; 95% CI: 0.19--0.78) and 'Unknown Smoking Status'.

![Forest plot analysis](TID-18-50-g004){#f0004}

![Subgroup analysis according to smoking status](TID-18-50-g005){#f0005}

DISCUSSION {#sec4}
==========

A comprehensive search of different databases was used to yield the most relevant results and incorporated the available epidemiologic evidence to explore the relationship between the *CYP2A6\*4* whole-gene deletion polymorphism and the risk of lung cancer. Nine case-control studies fulfilled the criteria addressing this issue. The analysis, involving 4385 lung cancer cases and 4142 controls, suggested that *CYP2A6* polymorphism significantly reduces the risk of lung cancer (pooled OR=0.39; 95% CI: 0.27--0.56), with homogeneity observed across studies (χ^2^=2.49, p=0.96, I^2^=0%). Thus, subgroup and sensitivity analyses were not explored.

There are two possible explanations for the finding of relative risk reduction as revealed by the analysis. First, *CYP2A6* is mainly found in the liver and other tissues such as the nasal epithelium, trachea, lung, and oesophagus^[@cit0036],[@cit0037]^. *CYP2A6* metabolizes a few but specific xenobiotics that include nicotine and some tobacco specific nitrosamines that enter the human body. Metabolic activation by *CYP2A6* enzymes generally produces a short-lived electrophile agent that reacts with DNA, causing DNA damage and inducing a tumour^[@cit0016]^. In tobacco smoke, *CYP2A6* is the main enzyme activating the tobacco-specific *N*-nitrosamines NNK and NNN, which are pro-carcinogens^[@cit0005],[@cit0006]^. Thus, in individuals with the inactive *CYP2A6* genotype, the *CYP2A6* enzyme might not affect metabolic activation of N-nitrosamines and subsequently reduce the risk of lung cancer. Second, *CYP2A6* is a major enzyme responsible for nicotine metabolism^[@cit0038]^, where inactive *CYP2A6* causes lower nicotine dependence and thus affects smoking behaviour^[@cit0039]-[@cit0041]^.

Of the included studies, only three studies^[@cit0012],[@cit0031],[@cit0032]^ recruited only smokers as participants; the remaining studies had mixed populations of smokers and never-smokers. The mixed-smoker status studies yielded non-significant findings or smaller risk estimates, which may be explained by the fact that the probability of lung cancer occurrence may be similar among never-smokers with different *CYP2A6* genotypes, where the resulting phenotype is not expressed in people who do not smoke. Thus, when the original studies included both smokers and non-smokers, the association between the *CYP2A6* polymorphism genotype and risk of lung cancer may have been attenuated. This may explain why some of the studies did not find any significant association^[@cit0019],[@cit0020],[@cit0029],[@cit0042]^.

Besides that, cigarette smoking is strongly associated with squamous cell carcinoma compared to adenocarcinoma^[@cit0043]-[@cit0045]^. However, in the present meta-analysis, all but one study included different lung cancer histology types; Hosono et al.^[@cit0012]^ only recruited squamous cell carcinoma cases. The study by Islam et al.^[@cit0029]^ had the highest proportion of squamous cell carcinoma cases (43.39%), while the other studies had 24.5--28.4% squamous cell carcinoma cases^[@cit0030]-[@cit0032],[@cit0034]^. These differences in the proportion of histological types might explain the discrepancy of the findings among the studies on *CYP2A6* polymorphism and lung cancer risk.

Limitations {#sec4.1}
-----------

The present meta-analysis findings should be interpreted with caution. Six studies did not stratify the smoking status to assess the association between *CYP2A6* polymorphism and lung cancer. Therefore, the true relationship between *CYP2A6* polymorphism and risk of lung cancer in current-smokers and never-smokers could not be tested in these six studies. In addition, lung cancer might arise due to occupational carcinogen exposure, such as organic dust and silica dust^[@cit0046],[@cit0047]^, which may confound the association between *CYP2A6* polymorphism and lung cancer risk. However, none of the included studies adjusted for occupational carcinogen hazard exposure originally. The relationship may be also affected by differences in the demographic characteristics and socioeconomic class of the respondents^[@cit0048]^, which some of the studies did not mention.

CONCLUSIONS {#sec5}
===========

The evidence from the case-control studies included in the present meta-analysis shows that people with *CYP2A6\*4* whole-gene deletion have a decreased risk of lung cancer. Further research is needed to identify any potential confounding factors that may impact this association.
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